A Study of Capmatinib in Lung Cancer Patients
Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!
Summary
- Eligibility
- for people ages 18-90 (full criteria)
- Location
- at Sacramento, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Li Tianhong
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UC Davis
- Li Tianhong
Associate Professor, Hematology and Oncology, School of Medicine. Authored (or co-authored) 65 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Novartis Pharmaceuticals
- Links
- Sign up for this study
- ID
- NCT04926831
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- Expecting 38 study participants
- Last Updated